x min read

4 Penny Stocks on the Rise: ETEK MDVL RVVTF TRVI

4 Penny Stocks on the Rise: ETEK MDVL RVVTF TRVI
Published on
April 18, 2022
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook

Today, one needs to be quick to take profits and go where the opportunities are. For us and our subscribers here at Insider Financial, that means trading both OTC and Nasdaq stocks.Our subscribers have plenty of opportunities in OTC, Nasdaq, and NYSE penny stocks with low floats, news, and a significant short position.Smart investors know that if you want to make the big money off a small account, the place to be is in penny stocks. There are many good penny stocks that can boost your portfolio’s value in the long term. We preach the key to trading penny stocks for investors is finding momentum BEFORE it happens and ahead of the crowd.[embed]https://www.youtube.com/watch?v=-2p9x7CJwaA[/embed]We alert our subscribers with our best ideas before our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here.In this article, we take a look at 4 hot penny stocks that can do well in the following weeks. They are Eco-Tek Group, Inc (OTCPK: ETEK), Medavail Holdings Inc (NASDAQ: MDVL), Revive Therapeutics Ltd (OTCQB: RVVTF), and Trevi Therapeutics Inc (NASDAQ: TRVI). Penny Stocks #1 ETEK Penny Stocks #2 MDVL Penny Stocks #3 RVVTF Penny Stocks #4 TRVI


Eco-Tek Group, Inc had an impressive week, surging over 130% since April 8 to trade at $0.0037, the highest since February. If it breaks above $0.004, the Pink Current stock can return to October levels when it peaked near $0.008 to establish the highest since 2014.ETEK currently has no operations, as it dumped its old business of green lubrication and filtration products. It has been in the process of seeking a reverse merger candidate for months, and we first shared our bullish expectations in September last year. Companies obtaining the Pink Current status and getting ready for mergers may hide great opportunities for early investors. ETEK has a nice share structure, with authorized shares almost maxed out.Last year, ETEK hired Emergent LLC to handle the regulatory requirements. Investors found out that it was targeting an AI business for a reverse merger. Recently, Emergent transferred the majority voting control of NuGene International, Inc (OTCPK: NUGN) to Livento Group LLC. The deal we reported last month bodes well for ETEK, as it shows that Emergent can help companies find the right merger or acquisition candidates. NUGN has tripled in price since it changed business direction in March.https://twitter.com/EmergentLlc/status/1513523212503728130While it’s hard to find any hints on ETEK’s merger candidate, the $20 million company is still a great bet, with the share price likely to explode when the deal is officially announced.


Medavail Holdings Inc has had a great month so far, gaining over 170% during the last two weeks. The initial price surge came on April 8, when over 190 million shares changed hands on that day alone – an absolute record since it went public more than a decade ago. During the first week of the month, the share price surged from less than $1 to $2.4 on April 8. After some volatile days, the stock is now trading at $2.44, hitting the highest level since November last year. Thus, following months of bearish pressure, MDVL is ready to reverse the rhetoric to expand its market cap, which recently broke above $170 million.MDVL is a tech-enabled retail pharmacy technology and services company that develops and commercializes self-service pharmacy, mobile application, kiosk, and drive-thru solutions in the US and Canada. It operates in two segments, Retail Pharmacy Services and Pharmacy Technology. The company's MedCenter enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without on-site clinics, and other locations where on-site prescription dispensing is desired. It also owns and operates SpotRx, a retail pharmacy platform.On April 4, the company announced the first closing of a private placement for the sale of about 37.6 million shares of common stock at an offering price of $1.0625 per share, together with the issuance of warrants to purchase approximately 18.8 million shares of common stock. The first closing of the private placement resulted in gross proceeds to MedAvail of $40 million. It plans to use the capital for general corporate purposes and to fund its strategic initiatives.The latest price surge came after an insider purchase disclosed by MedAvail’s (MDVL) top institutional holder Redmile Group in connection with the private placement. Analysts tend to agree that the main reason behind the sudden spike was the difficulty in borrowing shares to short.It remains to be seen whether the current bullish mood is sustainable, but the good news is that Zacks upgraded the stock to Buy, reflecting an upward trend in earnings estimates - one of the most relevant drivers impacting stock prices.


Another company operating in the healthcare sector is Revive Therapeutics Ltd, which is an OTCQB member. The share price of this COVID play has gained over 85% during the last five days alone to trade at $0.24, bouncing back from the recent bottom at $0.12, the lowest level since October 2020. We first reported on Revive during the second half of 2020, when the stock was trading near $0.20. The company, which has been developing a treatment for COVID-19, saw its share price breaking above $0.5 later the same year, but it gave up in 2021 after months of tension near $0.40, probably because concerns over the COVID pandemic have faded away.RVVTF is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations. Currently, Revive is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and treat ischemia and reperfusion injury from organ transplantation.RVVTF’s rebound intensified after the company provided an update on its FDA Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine. The Data Safety and Monitoring Board are scheduled to meet this quarter to evaluate the current clinical and safety data to either make recommendations on the study or advise on potentially halting the study early due to positive efficacy based on other clinical outcomes evaluated, such as the rate of sustained clinical resolution of symptoms of COVID-19. RVVTF believes that with the Omicron variant, including the BA.2 variant, being the dominant strain over the Delta variant and COVID-19 hospitalizations in the US in decline, there is an urgent unmet need to treat symptom resolutions in addition to preventing hospitalizations.CEO Michael Frank said:

“With COVID-19 cases on the rise and the need for alternative oral treatments that is relevant to the current state of the disease, we believe that Bucillamine’s anti-inflammatory and antiviral properties offers an alternative potential solution that is urgently needed globally to fight COVID-19 and allow for people to improve their quality of life.”

Investors are bullish on this $80 million company because of a recent study that showed Bucillamine doesn’t not interfere with vaccine antibodies, unlike most other Rheumatoid drugs.https://twitter.com/revivethera/status/1515735451394469891Meanwhile, the number of COVID cases has slowed down, but it’s still considered a threat, especially as China is locking down entire cities and is experiencing record figures. It still makes sense to watch RVVTF and its Bucillamine trial.


Trevi Therapeutics Inc continues to follow the bullish path that started to form at the end of February near $0.50. Now the NASDAQ-listed biotech stock is trading close to $3.3, hitting the highest since October 2020.TRVI is a clinical-stage biopharmaceutical company that develops and sells Haduvio to treat serious neurologically mediated conditions. Haduvio is an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation.Earlier this month, TRVI entered into an agreement with several healthcare-focused institutional investors for the purchase in a private placement priced at the market for gross proceeds of approximately $55 million, which is a considerable amount for the $120 million company. Frazier Life Sciences and Venrock Healthcare Capital Partners are co-lead investors in the private placement, and Fairmount and New Enterprise Associates are also taking part.TRVI will use the net proceeds from the private placement for the clinical development of Haduvio for chronic cough in idiopathic pulmonary fibrosis patients as well as for working capital and other general corporate purposes. The private placement was scheduled to close on or about April 11.It’s worth noting that the general public owns less than 20% of this stock, with half of the shares being held by venture capital and private equity firms. This reflects the great long-term value of TRVI.The company’s latest financial report revealed that Haduvio trials showed promising results. Jennifer L. Good, President and CEO of TRVI, said:

“We have made considerable progress on our two development programs with positive interim analysis results from our Phase 2 CANAL study for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and the completion of enrollment in our Phase 2b/3 PRISM study for the treatment of pruritus due to prurigo nodularis (PN). We were very pleased to see the strong magnitude of response and consistent results of Haduvio in the interim analysis for chronic cough in IPF. These results further support our belief in the overall mechanism of Haduvio and the potential to treat both chronic cough and chronic pruritus in various conditions. Chronic cough in IPF and pruritus in PN are both serious and debilitating conditions with no currently approved therapies and each of them potentially represents a significant opportunity to address an unmet need in the market.”

The exclusiveness of Haduvio may help TRVI ascend to new highs, so make sure to keep an eye on the trial results.


Now is a great opportunity to invest in top penny stocks with great potential. Our job is to identify the best penny stocks with strong fundamentals and let our subscribers pick the ones they like to build a well-diversified portfolio.Buying dips and selling rips as swing trades remains the best strategy in the stock market. Still, whenever a hot stock is in the middle of a bull run, we recommend our subscribers to book profits.It’s very important to eye penny stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.Remember, all you need is one or two penny stocks to run in order to crush the market averages.As always, good luck to all (except the shorts)!


Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.